Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Colinz LaboratoriesBOM:531210 -2.28%65 ROE % is 3.39% as of Dec. 2025, which is 6% above its 10-year median of 3.21. GuruFocus rates BOM:531210 with a GF Score™ of 65/100 and a GF Value™ of ₹42.35 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 937 Drug Manufacturers companies, Colinz Laboratories ranks worse than 52.83% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Colinz Laboratories ROE % Related Terms
Colinz Laboratories ROE % Historical Data
* Premium members only.
The historical data trend for Colinz Laboratories's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Colinz Laboratories's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Colinz Laboratories ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Colinz Laboratories's ROE % distribution charts can be found below:
* The bar in red indicates where Colinz Laboratories's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Colinz Laboratories (BOM:531210) has a ROE % of 3.39% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Colinz Laboratories and its competitors. This is near median its historical median of 3.21. Over the past decade, Colinz Laboratories' ROE % has ranged from 1.52 to 5.71. According to the industry distribution chart, Colinz Laboratories ranks #495 out of 937 companies in the Drug Manufacturers industry, placing it in the top 52.8%.
Is Colinz Laboratories' ROE % too high?
Colinz Laboratories' current ROE % of 3.39% is near median its 10-year median of 3.21. Over the past 10 years, this metric has ranged from a low of 1.52 to a high of 5.71. The Drug Manufacturers industry median ROE % is 6.04. Colinz Laboratories' value of 3.39% is 43.9% below this industry median. Based on the distribution chart, Colinz Laboratories ranks #495 out of 937 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Colinz Laboratories has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Colinz Laboratories' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Colinz Laboratories ranks #495 out of 937 companies for ROE %. This places Colinz Laboratories in the lower half of its industry. The industry median ROE % is 6.04. Colinz Laboratories' value of 3.39% is 43.9% below this benchmark. Historically, Colinz Laboratories' own ROE % has ranged from 1.52 to 5.71 over the past decade. While the company's 10-year median is 3.21 vs. the industry median of 6.04, Colinz Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.04, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Colinz Laboratories's current ROE % of 3.39% is 43.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Colinz Laboratories and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Colinz Laboratories's current ROE % is 3.39%, which is near median its own 10-year median of 3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Colinz Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Colinz Laboratories (BOM:531210) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹42.35, compared to a current price of ₹80.13 — trading 89.2% above its estimated fair value. The current ROE % is 3.39%, which is near median its 10-year median of 3.21 and 43.9% below the Drug Manufacturers industry median of 6.04. Colinz Laboratories' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Colinz Laboratories (BOM:531210), the current ROE % is 3.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Colinz Laboratories (BOM:531210) Overvalued in 2026?
Based on GuruFocus' analysis, Colinz Laboratories stock appears to be overvalued.
The current stock price of ₹80.13 is trading 89.2% above its estimated GF Value™ of ₹42.35.
GuruFocus considers Colinz Laboratories to be Significantly Overvalued.
Key valuation signals for BOM:531210:
ROE %: 3.39% (near median its 10-year median of 3.21)
GF Value™: ₹42.35 vs. price of ₹80.13 (89.2% above fair value)
Industry Position: 43.9% below the Drug Manufacturers median (#495 of 937)
No single metric tells the full story. See the BOM:531210 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Colinz Laboratories Ltd is an India-based company engaged in manufacturing and trading in Pharmaceutical formulations. It offers formulations in the products category of ayurvedic, allopathic, and nutraceuticals. The company manufactures pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, and others. It also has certain specialized products for gynecology, cardiology, gastroenterology, and others. The group derives revenue from the sale of its products in India.
65GF Score
Get the complete analysis for BOM:531210
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531210 has been successfully added to your 
